Abstract Objective Combinations of pharmacological agents are essential for disease control and prevention, offering many advantages over monotherapies, with one these being drug synergy. The state-of-the-art method to profile synergy in preclinical research is by using dose–response matrices disease-appropriate models, however this approach frequently labour intensive cost-ineffective, particu...